[Infostock Daily= Reporter Park Sang-In] Samsung Bioepis has launched its third phase of global clinical trials of the ophthalmic disease treatment 'SB15' (component name Apple Liverscept).
Samsung Bioepis recently unveiled SB15's Phase 3 clinical trial plan and released it through the global clinical trial information website 'Clinical Trials'. SB15 is a biosimilar of the U.S. regeneron "Ailia".
Ailia is an ophthalmic disease treatment developed by Regeneron the United States and has indications for macular degeneration and diabetic macular edema. Aylia's global sales last year amounted to $7.54 trillion (about 8.7 trillion won).
Through this clinical trial, Samsung Bioepis plans to conduct a comparative study on the efficacy, safety, pharmacokinetics and immunogenicity between SB15 and original medicines (Ailia) in 446 patients with macular degeneration in 10 countries including Korea and the United States by February 2022.
An official of Samsung Bioepis said, "Through the successful development of SB15, we will secure a product portfolio in various fields to enhance the accessibility of patients to high quality biopharmaceuticals."
Reporter Park Sang-In si2020@infostock.co.kr
